Skip to content
montabiosciences.commontabiosciences.com
  • Home
  • About us
    • Company History
    • Management
    • Board of Directors
    • Founders
  • Technology
    • Todays Challenges
    • Cancer Treatment
    • Cancer Immunotherapy
    • Development
    • References
  • News
  • Contact Us

Publications by the MonTa Team in the TLR7 field

Formulation of TLR7 for immunotherapy

Targeted delivery of TLR7 formulations to the DCIR receptor

Publications on lead TLR7 agonist

Publication demonstrating strong synergy of TLR7 and PD1 therapy and ability of TLR7 formulation to turn “Cold tumors into Hot tumors”

The MonTa Biosciences TLR7 agonist show protective immunity in mice

Pulmonary adminstration of TLR7 agonist induce protective immunity

Discovery of TLR7 agonist 1V270 and stimulation of CTL response in a vaccination model

TLR7 agonist 1V270 show better off target profile than Imiquimod and synergize with CTLA-4 therapy in cancer model 

TLR7 agonist 1V270 induce anti-metastatic activity in monotherapy by systemic route and enhance and activate mDCs and CD8 T-cells in lymph nodes and increase CD8 T-cell tumor infiltration

Demonstrated TLR7 synergy with existing treatments

Synergistic effect by combining TLR7 with CD20 in mouse models 

TLR7 antitumor activity combined with radiotherapy depends on myeloid cells

TLR7 combinatoin with radiotherapy induce complete remission in mouse models

Enhanced therapeutic activity in combination with PD1 therapy 

MonTa Biosciences ApS

Diplomvej 381
2800 Kgs. Lyngby
Denmark

VAT nr. 36697016

    Privacy statement
    MonTa Biosciences - Cancer Therapeutics of Tomorrow
    • Home
    • About us
      • Company History
      • Management
      • Board of Directors
      • Founders
    • Technology
      • Todays Challenges
      • Cancer Treatment
      • Cancer Immunotherapy
      • Development
      • References
    • News
    • Contact Us